| Assessment Status |
NCPE Assessment Process Complete |
| HTA ID |
- |
| Drug |
Daclatasvir |
| Brand |
Daklinza® |
| Indication |
In combination with other medicinal products for the treatment of chronic hepatitis C (genotype 1,3 and 4) |
| Rapid review commissioned |
05/08/2014 |
| Rapid review completed |
12/09/2015 |
| Rapid review outcome |
Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant |
01/12/2014 |
| NCPE assessment completed |
29/05/2015 |
| NCPE assessment outcome |
Reimbursement recommended for certain subgroups |
